SCHEMBL17891417

SCHEMBL17891417

Cc1ccc(N2CCN(C)CC2)cc1N(C)c1ccc(Oc2nc(O)c3ccncc3n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 19/20 0.53
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20724133 0.91 KDM4C (0.45) KDM4CCCNCCDK8
SCHEMBL17891416 0.90 KDM4C (0.52) KDM4CCCNCCDK8
SCHEMBL29542484 0.90 KDM4C (0.52) KDM4CCCNCCDK8
SCHEMBL17602090 0.89 KDM4C (0.65) KDM4CCCNCCDK8
SCHEMBL29542716 0.88 KDM4C (0.50) KDM4CCCNCCDK8
SCHEMBL17891448 0.88 KDM4C (0.50) KDM4CCCNCCDK8
SCHEMBL30139678 0.86 KDM4C (0.68) KDM4C
SCHEMBL17602139 0.86 KDM4C (0.68) KDM4C
SCHEMBL17602100 0.86 KDM4C (0.68) KDM4C
SCHEMBL29541985 0.86 KDM4C (0.68) KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US claimed
EP-3430008-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-05-18 — — EP disclosed
EP-3430008-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-05-18 — — EP disclosed
US-10208039-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-19 — — US disclosed
US-10208039-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-19 — — US disclosed
US-10202381-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-12 — — US disclosed
US-10202381-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-02-12 — — US disclosed
EP-3430008-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2019-01-23 — — EP disclosed
US-20180297999-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-10-18 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 — — US disclosed
WO-2017161012-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-09-21 — — WO disclosed
WO-2017161012-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-09-21 — — WO disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885CCNC 1194/4885CDK8 297/4885
US-10030017-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885CCNC 1194/4885CDK8 297/4885
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885CCNC 1194/4885CDK8 297/4885
US-20180297999-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A KDM4C 9/4885CCNC 1194/4885CDK8 297/4885
US-10202381-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885CCNC 1194/4885CDK8 297/4885
US-10208039-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A KDM4C 9/4885CCNC 1194/4885CDK8 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback